John D Roberts, MD
Professor of Internal MedicineDownloadHi-Res Photo
Cards
Appointments
Hematology
Primary
Contact Info
About
Titles
Professor of Internal Medicine
Biography
Dr Roberts has worked at the University of Vermont, Virginia Commonwealth University, and Yale University. He is board certified in internal medicine, pediatrics, medical oncology, and hospice and palliative care. He did laboratory and clinical research, including scores of clinical trials, while practicing medical oncology and caring for adults with sickle cell disease. He has done research administration, academic administration, and served on multiple IRBs. He has served on committees of the American Society of Hematology, the American Society of Clinical Oncology, and the National Institutes of Health. Current activities are clinical research and consulting for non-governmental organizations and the pharmaceutical and pharmacy industries.
Appointments
Hematology
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- University of Vermont (1984)
- Resident
- University of North Carolina at Chapel Hill (1980)
- MD
- University of Pennsylvania (1976)
- AB
- Harvard University, Social Studies (1972)
Board Certifications
Hospice & Palliative Medicine
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2023
- Original Certification Date
- 2012
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1985
Pediatrics
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 1982
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1980
Research
Overview
Medical Research Interests
Anemia, Sickle Cell
Research at a Glance
Yale Co-Authors
Frequent collaborators of John D Roberts's published research.
Publications Timeline
A big-picture view of John D Roberts's research output by year.
Research Interests
Research topics John D Roberts is interested in exploring.
Jeanne Hendrickson, MD
Joanna Cole, RN, APRN, FNP (BC)
Raisa Balbuena-Merle, MD, MHS
Alexa Siddon, MD
Ariadna Forray, MD
Christopher Tormey, MD
121Publications
4,190Citations
Anemia, Sickle Cell
Publications
2021
Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy
Curtis SA, Raisa BM, Roberts JD, Hendrickson JE, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion And Apheresis Science 2021, 61: 103304. PMID: 34782244, PMCID: PMC9838733, DOI: 10.1016/j.transci.2021.103304.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsChronic exchange transfusionsHealth care utilizationCare utilizationExchange transfusionPain impactDisease characteristicsChronic red blood cell transfusionsRed blood cell transfusionLower health care utilizationSickle Cell Disease PainExchange transfusion therapyAcute care utilizationBlood cell transfusionSimilar disease characteristicsPatient-reported outcomesLength of staySickle cell diseaseQuality of lifeCause admissionsCell transfusionNeuropathic painOpioid prescriptionsWorst painAcute painAdult patients
2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia & Lymphoma 2020, 62: 1187-1194. PMID: 33356689, PMCID: PMC8106643, DOI: 10.1080/10428194.2020.1861270.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsStable diseaseAcute leukemiaDay 1Phase 1 dose-escalation studyRefractory acute leukemiaDose-escalation studyPhase 1 studyWhole-exome sequencingComplete pathologicKaryotypic responseAdult patientsQTc prolongationFirst patientMyelodysplastic syndromeTreatment strategiesBlast crisisPatientsExceptional responseKaryotypic aberrationsBelinostatGood responseBortezomibAMLLeukemiaFurther investigationDaily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints
Curtis SA, Brandow AM, DeVeaux M, Zeltermam D, Devine L, Roberts JD. Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints. Cannabis And Cannabinoid Research 2020, 5: 255-262. PMID: 32923662, PMCID: PMC7480712, DOI: 10.1089/can.2019.0036.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSickle cell diseaseDaily cannabis usersAnnual emergency room visitsSevere pain crisesEmergency room visitsHealth care utilizationCannabis usersCross-sectional studyPatient-reported measuresQuality of lifeSimilar disease severityHydroxyurea usePain crisisPain complaintsHospital admissionCare utilizationRoom visitsPain impactSeverity scoreDisease showAnnual admissionsCell diseaseER useDaily cannabisDisease severityMedical marijuana certification for patients with sickle cell disease: a report of a single center experience
Curtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances 2020, 4: 3814-3821. PMID: 32790846, PMCID: PMC7448584, DOI: 10.1182/bloodadvances.2020002325.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOpioid useMedical marijuanaSickle cell disease (SCD) reportBaseline opioid useSingle-center experienceHealth care utilizationSickle cell diseaseOpioid utilizationClinical characteristicsMost patientsCenter experienceCare utilizationSCD patientsInpatient hospitalizationRandom patientsAdmission ratesCell diseasePatientsRetrospective dataDisease reportsStudy periodHealth careCannabis productsCannabisEdible cannabis productsUrinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use
Koch CD, Xu L, Curtis SA, Roberts JD, Bunch DR, El-Khoury JM. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. Clinica Chimica Acta 2020, 510: 515-521. PMID: 32795544, DOI: 10.1016/j.cca.2020.08.014.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCannabis useUrine samplesLoss of appetiteMinor cannabinoidsRapid LC-MS/MSDronabinol groupDronabinol therapyDronabinol useSevere nauseaPain managementPositive subjectsNormal controlsTherapeutic potentialProspective sampleClinical urine samplesCancer chemotherapySpecific populationsCannabisCannabinoidsMetabolite concentrationsDronabinolLC-MS/MSNegative controlDetection of cannabisCannabidiolBuilding access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD, Lanzkron S. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances 2020, 4: 3804-3813. PMID: 32785684, PMCID: PMC7448595, DOI: 10.1182/bloodadvances.2020001743.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSickle cell diseaseSCD centerCell diseaseAdult sickle cell diseaseAcute care utilizationManagement of adultsModel of careSickle cell careHealth care professionalsHealth system levelSCD guidelinesMultisystem illnessSCD careCare utilizationEarly mortalityCenter designationClinical effectivenessClinical centersCare professionalsHematology providersMore cliniciansCare deliveryMost childrenBlood disordersCareUtilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program
Rousseau R, Weisberg DF, Gorero J, Parwani V, Bozzo J, Kenyon K, Smith C, Cole J, Curtis S, Forray A, Roberts JD. Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program. PLOS ONE 2020, 15: e0236360. PMID: 32706825, PMCID: PMC7380627, DOI: 10.1371/journal.pone.0236360.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSickle cell diseaseCell diseaseYale-New Haven HospitalAcute care servicesCare of adultsPoor socio-economic statusPersonalized care planSickle Cell ProgramNew Haven HospitalSingle nursing unitParenteral opioidsPain controlClinic visitsMost patientsPain managementChronic painOutpatient visitsPrimary complaintEmergency departmentPrimary careInpatient daysCare plansCare servicesSocio-economic statusNursing units
2019
Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types
Curtis S, Forray A, Hendrickson J, Roberts J. Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood 2019, 134: 1028. DOI: 10.1182/blood-2019-129106.Peer-Reviewed Original ResearchConceptsSickle cell diseaseNeuropathic pain qualitiesNeuropathic painNociceptive painPain impactBaseline painED usePain qualityWorse sleepOpioid usePain groupChronic painCell diseaseEpisode frequencyOutcomes Measurement Information System (PROMIS) domainsAdult Sickle Cell QualityAverage daily opioid useHigher C-reactive proteinYale-New Haven HospitalHigh ED useWorse clinical outcomesC-reactive proteinDaily opioid useEmergency department useHalf of adultsCase Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease
Smith W, Sop D, Johnson S, Lipato T, Ferlis M, Mcmanus C, Guy M, Hartigan S, Holt E, McHenry C, Roberts J. Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease. Blood 2019, 134: 2104. DOI: 10.1182/blood-2019-130441.Peer-Reviewed Original ResearchConceptsVirginia Commonwealth University Medical CenterCommunity health workersAdvanced practice providersSickle cell diseaseReadmission ratesInpatient daysCase managementSCD adultsOutpatient visitsCare utilizationHigh utilizersMedical homeCell diseaseHealth workersInpatient health care utilizationAdult SCD patientsED return rateAcute care utilizationHospital readmission ratesHealth care utilizationEmergency department managementNumber of patientsTotal inpatient daysPatient-provider relationshipTruven Health AnalyticsStatewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease
Roberts J, Andemariam B, Bozzo J, Du C, Curtis S, Latham D, Cyr M, Magras L. Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease. Blood 2019, 134: 517. DOI: 10.1182/blood-2019-124462.Peer-Reviewed Original ResearchConceptsSickle cell diseaseED/hospitalCommunity health networksED visitsED visit ratesEmergency departmentHospital visitsClinical team membersCell diseaseHealth NetworkHospitalization ratesHospital utilizationVisit ratesAdvisory CommitteeUtilization dataICD-9/ICDInstitutional review board approvalMedicaid programAmbulatory care servicesService utilization patternsTruven Health AnalyticsAge 16 yearsQuality improvement projectReview board approvalMann-Whitney U test
Academic Achievements & Community Involvement
activity Community Health Network of Connecticut
Public ServiceConsultantDetailsWorking to improve patterns of health care services utilization by adults with Medicaid living with sickle cell disease.2014 - 2021honor 2012 Harry Hines Award (NCI CCOP Principal Investigator of the Year)
National AwardNational Cancer InstituteDetails09/25/2012activity National Cancer Institute
Peer Review Groups and Grant Study SectionsMemberDetailsClinical Oncology Study Section07/01/2008 - 06/30/2012